rifabutin

Summary

Summary: A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.

Top Publications

  1. Bhagat N, Read R, Rao N, Smith R, Chong L. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology. 2001;108:750-2 pubmed
    To report the occurrence of rifabutin-associated hypopyon uveitis in human immunodeficiency virus (HIV)-negative immunocompetent individuals. Retrospective case series...
  2. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, Yokoi T. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011;82:1747-56 pubmed publisher
    Rifamycins such as rifampicin, rifabutin, and rifapentine are used for the treatment of tuberculosis and induce various drug-metabolizing enzymes...
  3. Coutinho A, Cheema D, Pereira P, Souza Filho J, Burnier M. Corneal endothelial deposits associated with rifabutin use. J Ocul Pharmacol Ther. 2005;21:166-9 pubmed
    ..this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin. Case series consisting of 3 patients treated with rifabutin were retrospectively studied...
  4. Yuen L, Leslie D, Coloe P. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol. 1999;37:3844-50 pubmed
    ..resistance to isoniazid, 88% were resistant to rifampin on first isolation, and 81% showed cross-resistance with rifabutin. On the basis of the demographic data provided for the patients infected with the rifampin-resistant strains, 90%..
  5. Sintchenko V, Chew W, Jelfs P, Gilbert G. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology. 1999;31:257-60 pubmed
    ..The aim of this study was the detection of rpoB gene mutations and rifabutin resistance in MDRTB strains recently isolated in Australia by a line probe assay (INNO-LiPA Rif...
  6. Gisbert J, Calvet X, Bujanda L, Marcos S, Gisbert J, Pajares J. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter. 2003;8:90-4 pubmed
    ..Our aim was to evaluate the efficacy and tolerability of a rifabutin-based regimen in patients with two consecutive H. pylori eradication failures. Prospective multicenter study...
  7. Tan Y, Hu Z, Zhao Y, Cai X, Luo C, Zou C, et al. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. J Clin Microbiol. 2012;50:81-5 pubmed publisher
    We aimed to study the distribution and contribution of mutations in the rpoB whole gene in rifampin-resistant/rifabutin-resistant (RIF(r)/Rfb(r)) (or RIF/Rfb cross-resistant) clinical Mycobacterium tuberculosis isolates. One standard M...
  8. Selby W, Pavli P, Crotty B, Florin T, Radford Smith G, Gibson P, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007;132:2313-9 pubmed
    ..We report a prospective, parallel, placebo-controlled, double-blind, randomized trial of 2 years of clarithromycin, rifabutin, and clofazimine in active Crohn's disease, with a further year of follow-up.
  9. Toracchio S, Capodicasa S, Soraja D, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis. 2005;37:33-8 pubmed
    b>Rifabutin has been empirically used in Helicobacter pylori infections resistant to triple therapy. There are no data on primary and secondary resistance to rifabutin and its use in specific cases...

More Information

Publications62

  1. Perri F, Festa V, Clemente R, Villani M, Quitadamo M, Caruso N, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96:58-62 pubmed
    A novel rifabutin-based therapy is able to cure Helicobacter pylori infection in most patients who have failed eradication after standard proton pump inhibitor (PPI)-based triple therapy...
  2. Gisbert J, Gisbert J, Marcos S, Moreno Otero R, Pajares J. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-74 pubmed
    ..To compare rifabutin and levofloxacin rescue regimens in patients with two consecutive Helicobacter pylori eradication failures...
  3. Munster P, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and . Clin Cancer Res. 2001;7:2228-36 pubmed
    ..These findings suggest that inhibition of Hsp90 function by 17-AAG enhances the apoptotic effects of cytotoxic agents. The sequence of drug administration and the RB status significantly influence efficacy. ..
  4. van Ingen J, Aarnoutse R, de Vries G, Boeree M, van Soolingen D. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis. 2011;15:990-2 pubmed publisher
    ..Based on drug susceptibility test results, three patients were treated with 12-15 month rifabutin-based regimens and one with a 12-month RMP-based regimen...
  5. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother. 1998;42:621-8 pubmed
    We compared the in-vitro antimycobacterial activities of rifabutin and KRM-1648, two rifamycin derivatives, with that of rifampicin against 163 strains of Mycobacterium tuberculosis...
  6. Rakitina T, Vasilevskaya I, O Dwyer P. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res. 2003;63:8600-5 pubmed
    ..These data support an interaction between 17-AAG and components of the NF-kappaB pathway in the modulation of oxaliplatin sensitivity in colon cancer cells. ..
  7. Li J, Munsiff S, Driver C, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83-91 pubmed
    ..4-21.5). Among HIV-infected patients with TB, none of 57 patients treated with rifabutin-based regimens alone had ARR, and only 1 of 395 patients treated with rifabutin given in combination with a ..
  8. Boulanger C, Hollender E, Farrell K, Stambaugh J, Maasen D, Ashkin D, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305-11 pubmed publisher
    ..We examined the pharmacokinetics of rifabutin before and after the addition of lopinavir-ritonavir...
  9. Kawamura T, Tashiro E, Shindo K, Imoto M. SAR study of a novel triene-ansamycin group compound, quinotrierixin, and related compounds, as inhibitors of ER stress-induced XBP1 activation. J Antibiot (Tokyo). 2008;61:312-7 pubmed publisher
    ..All of four possessed 21-membered macrocyclic lactams including triene moieties. ..
  10. Solit D, Scher H, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003;30:709-16 pubmed
    ..These data suggest that inhibitors of Hsp90 may represent a novel strategy for the treatment of patients with prostate cancer and clinical trials to test this hypothesis are currently ongoing. ..
  11. Yamamoto K, Tashiro E, Imoto M. Quinotrierixin inhibited ER stress-induced XBP1 mRNA splicing through inhibition of protein synthesis. Biosci Biotechnol Biochem. 2011;75:284-8 pubmed
    ..Thus, we showed that quinotrierixin inhibited the ER stress-induced unfolded protein response, possibly due to its inhibitory activity of protein synthesis. ..
  12. Williamson B, Dooley K, Zhang Y, Back D, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366-9 pubmed publisher
    ..Drug-drug interactions during tuberculosis treatment are common. Induction by rifapentine and rifabutin is understudied...
  13. Heep M, Beck D, BayerdOrffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43:1497-9 pubmed
    ..032 to 2 microg/ml; MIC at which 50% of isolates are inhibited [MIC50], 0.25 microg/ml). The MIC50 of rifabutin was 0.008 microg/ml (n = 16). All resistant laboratory mutants of H...
  14. Finch C, Chrisman C, Baciewicz A, Self T. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-92 pubmed
    ..b>Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin...
  15. Chen H, Yu M, Huang W, Wu M, Chang Y, Che C, et al. Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis. J Clin Microbiol. 2012;50:2085-8 pubmed publisher
    Rapid assays are still needed to detect rifabutin (RFB) susceptibility for proper tuberculosis treatment...
  16. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol. 2000;31:222-5 pubmed
    ..In the present pilot study, a recently described rifabutin-based triple therapy was evaluated after preceding failure of triple therapy...
  17. Kawamura T, Tashiro E, Yamamoto K, Shindo K, Imoto M. SAR study of a novel triene-ansamycin group compound, quinotrierixin, and related compounds, as inhibitors of ER stress-induced XBP1 activation. J Antibiot (Tokyo). 2008;61:303-11 pubmed publisher
    ..Moreover, we performed SAR study of twelve triene-ansamycin group compounds. The study showed that OH group at C-13 was crucial, and CH3 group at C-14 would be important for the XBP1 inhibitory activity. ..
  18. Zhang X, Fettner S, Zwanziger E, Rowell L, Salgo M. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother. 2011;55:680-7 pubmed publisher
    The effect of multiple doses of rifabutin (150 mg) on the pharmacokinetics of saquinavir-ritonavir (1,000 mg of saquinavir and 100 mg of ritonavir [1,000/100 mg]) twice daily (BID) was assessed in 25 healthy subjects...
  19. Anthony R, Schuitema A, Bergval I, Brown T, Oskam L, Klatser P. Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. Ann Clin Microbiol Antimicrob. 2005;4:9 pubmed
    ..In this study we have sequentially generated resistant strains to first rifampicin and then rifabutin. Portions of the rpoB gene were sequenced from 131 randomly selected mutants...
  20. Jo K, Ji W, Hong Y, Lee S, Kim W, Kim D, et al. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med. 2013;107:292-7 pubmed publisher
    We investigated the efficacy of rifabutin (RFB)-containing regimens for the treatment of RFB-susceptible, multidrug-resistant tuberculosis (MDR-TB)...
  21. Ford S, Chen Y, Lou Y, Borland J, Min S, Yuen G, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother. 2008;52:534-8 pubmed
    b>Rifabutin (RFB) is administered for treatment of tuberculosis and Mycobacterium avium complex infection, including use for patients coinfected with human immunodeficiency virus (HIV)...
  22. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004;206:149-57 pubmed
    ..This article reviews the current status and future prospects for the exploitation of Hsp90 as a new molecular target for cancer treatment. ..
  23. Yoshida S, Suzuki K, Iwamoto T, Tsuyuguchi K, Tomita M, Okada M, et al. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother. 2010;16:360-3 pubmed publisher
    We compared rifabutin susceptibility and rpoB mutations in 98 multi-drug-resistant strains of Mycobacterium tuberculosis (MDR-TB) by DNA sequencing and with a line probe assay using the commercially available INNO-LiPA Rif...
  24. Weiner M, Benator D, Burman W, Peloquin C, Khan A, Vernon A, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481-91 pubmed
    ..We performed a pharmacokinetic substudy of patients in a trial of treatment with twice-weekly rifabutin and isoniazid...
  25. Sharma S, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;:CD007545 pubmed publisher
    ..A weekly regimen of rifapentine plus INH has higher completion rates, and less liver toxicity, though treatment discontinuation due to adverse events is probably more likely than with INH. ..
  26. Gatti G, Di Biagio A, De Pascalis C, Guerra M, Bassetti M, Bassetti D. Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. Br J Clin Pharmacol. 1999;48:704-11 pubmed
    The purpose of the study was to compare the pharmacokinetic parameters of rifabutin obtained in a group of patients without wasting syndrome (NWS) with those obtained in a group with wasting syndrome (WS)...
  27. Wong W, Gu Q, Lam S, Fung F, Lai K, Hu W, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:553-60 pubmed
    To test the efficacy of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy for the second-line treatment of Helicobacter pylori infection. One hundred and nine patients who had failed previous H...
  28. Borody T, Pang G, Wettstein A, Clancy R, Herdman K, Surace R, et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:481-8 pubmed
    ..To test the efficacy of a modified triple regimen combining rifabutin, pantoprazole and amoxicillin as rescue therapy for patients in whom eradication of H...
  29. Jenny Avital E, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48:1471-4 pubmed publisher
    ..tuberculosis infection following concurrent treatment with rifabutin (dosage, 150 mg every other day) and a ritonavir-boosted HIV protease inhibitor during a prior episode of drug-..
  30. O CONNOR A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, et al. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci. 2013;182:693-5 pubmed publisher
    Helicobacter pylori eradication rates using conventional triple therapies are falling, making viable second-line and rescue regimens necessary. Levofloxacin, tetracycline and rifabutin are three efficacious antibiotics for rescue therapy.
  31. Awotesu O, Missotten T, Pitcher M, Lynn W, Lightman S. Uveitis in a patient receiving rifabutin for Crohn's disease. J R Soc Med. 2004;97:440-1 pubmed
  32. Sausville E, Tomaszewski J, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 2003;3:377-83 pubmed
    ..Evidence of modulation of Hsp90 partner molecules has been obtained in both surrogate and some tumor compartments. These very early results encourage additional clinical evaluations of 17AAG and related molecules. ..
  33. Jewelewicz D, Schiff W, Brown S, Barile G. Rifabutin-associated uveitis in an immunosuppressed pediatric patient without acquired immunodeficiency syndrome. Am J Ophthalmol. 1998;125:872-3 pubmed
    To describe a case of bilateral, symptomatic rifabutin-associated uveitis with hypopyon and vitreal opacities in an immunosuppressed pediatric patient without acquired immunodeficiency syndrome (AIDS). Case report...
  34. Golchin B, McClellan K. Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia. Br J Ophthalmol. 2003;87:798-9 pubmed
  35. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther. 2005;21:91-6 pubmed
    ..at secondary care level was treated using strategies including antibiotic sensitivity testing and the use of rifabutin- and furazolidone-based therapies...
  36. Dhople A, Williams S. The activity of rifabutin against Mycobacterium leprae in armadillos. Int J Antimicrob Agents. 1997;9:169-73 pubmed
    The activity of rifabutin (LM 427) against Mycobacterium leprae was evaluated in armadillos inoculated earlier with human-derived M. leprae. Rifabutin was administered daily at a dose of 6 mg/kg body weight/day...
  37. Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother. 2011;66:2075-82 pubmed publisher
    ..This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir...
  38. Chikamatsu K, Mizuno K, Yamada H, Mitarai S. [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains]. Kekkaku. 2009;84:631-3 pubmed
    To compare the susceptibility of rifampicin (RFP) and rifabutin (RBT) against multi-drug resistant Mycobacterium tuberculosis (MDR-TB). A total of 44 confirmed MDR-TB strains collected by Ryoken consortium and 97 susceptible M...
  39. Liu X, Li R. Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. J Chemother. 2001;13:563-8 pubmed
    The combination of rifabutin and ciprofloxacin is potentially useful for the treatment of disseminated Mycobacterium avium-intracellulare (MAC) diseases in HIV-infected patients...
  40. Cavusoglu C, Karaca Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect. 2004;10:662-5 pubmed
    The relationship between resistance to rifampicin and rifabutin and genetic alterations in the rpoB gene of 41 rifampicin-resistant isolates of Mycobacterium tuberculosis was evaluated...
  41. Skolik S, Willermain F, Caspers L. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm. 2005;13:483-5 pubmed
    b>Rifabutin-associated uveitis has been reported frequently in AIDS patients and more rarely in immunocompetent patients. It is characterized clinically by anterior acute uveitis...
  42. Benson C, Williams P, Currier J, Holland F, Mahon L, MacGregor R, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syn. Clin Infect Dis. 2003;37:1234-43 pubmed
    ..patients with bacteremic MAC disease were randomized to receive clarithromycin with either ethambutol (C+E), rifabutin (C+R), or both (C+E+R) for 48 weeks...
  43. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54:4440-5 pubmed publisher
    The drug-drug interaction between rifabutin (RFB) and darunavir/ritonavir (DRV/r) was examined in a randomized, three-way crossover study of HIV-negative healthy volunteers who received DRV/r 600/100 mg twice a day (BID) (treatment A), ..
  44. Kraft W, McCrea J, Winchell G, Carides A, Lowry R, Woolf E, et al. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004;44:305-13 pubmed
    Two studies examined the pharmacokinetics of indinavir and rifabutin when coadministered in healthy subjects...
  45. Benson C, Williams P, Cohn D, Becker S, Hojczyk P, Nevin T, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community P. J Infect Dis. 2000;181:1289-97 pubmed
    The efficacy and safety of clarithromycin and rifabutin alone and in combination for prevention of Mycobacterium avium complex (MAC) disease were compared in 1178 patients with AIDS who had < or =100 CD4 T cells/microL in a randomized,..
  46. Dooley K, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21-7 pubmed publisher
    ..This study evaluated the effect of RIF or rifabutin (RBT) on the pharmacokinetics of the investigational HIV integrase inhibitor, dolutegravir (DTG)...
  47. Siegal F, Eilbott D, Burger H, Gehan K, Davidson B, Kaell A, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS. 1990;4:433-41 pubmed
    We studied the tolerance of humans to rifabutin, a rifamycin with antimycobacterial and in vitro anti-HIV activity...
  48. Atkinson B, Bocanegra R, Graybill J. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother. 1995;39:2316-9 pubmed
    ..Mycobacterium haemophilum infection was utilized to compare treatment with azithromycin, ciprofloxacin, rifabutin, and the combination of clarithromycin with rifabutin. Following subcutaneous challenge with M...
  49. Skinner M, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1989;33:1237-41 pubmed
    We investigated the pharmacokinetics of rifabutin in 15 male patients as part of a phase I trial of the treatment of early symptomatic human immunodeficiency virus infection...
  50. Jacobs D, Piliero P, Kuperwaser M, Smith J, Harris S, Flanigan T, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol. 1994;118:716-22 pubmed
    We studied patients with a new anterior uveitis syndrome associated with rifabutin use.
  51. Neckers L, Lee Y. Cancer: the rules of attraction. Nature. 2003;425:357-9 pubmed
  52. Zou J, Guo Y, Guettouche T, Smith D, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94:471-80 pubmed
    ..Hsp90-containing HSF1 complex is present in the unstressed cell and dissociates during stress. We conclude that Hsp90, by itself and/or associated with multichaperone complexes, is a major repressor of HSF1. ..
  53. Arlander S, Eapen A, Vroman B, McDonald R, Toft D, Karnitz L. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem. 2003;278:52572-7 pubmed
    ..Collectively, our studies identify Chk1 as a novel Hsp90 client and suggest that pharmacologic inhibition of Hsp90 may sensitize tumor cells to chemotherapeutic agents by disrupting Chk1 function during replication stress. ..